{'52WeekChange': 0.50766134,
 'SandP52WeekChange': 0.0644362,
 'address1': '10628 Science Center Drive',
 'address2': 'Suite 200',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 60,
 'askSize': 800,
 'averageDailyVolume10Day': 279737,
 'averageVolume': 388101,
 'averageVolume10days': 279737,
 'beta': None,
 'beta3Year': None,
 'bid': 60.02,
 'bidSize': 800,
 'bookValue': 10.626,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Diego',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 62.01,
 'dayLow': 59.16,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -19.13,
 'enterpriseToRevenue': None,
 'enterpriseValue': 1780207488,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 63.775143,
 'fiftyTwoWeekHigh': 72.025,
 'fiftyTwoWeekLow': 31.304,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 25795335,
 'forwardEps': -4.62,
 'forwardPE': -12.991343,
 'fromCurrency': None,
 'fullTimeEmployees': 102,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.06306,
 'heldPercentInstitutions': 0.88183,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/tptherapeutics.com',
 'longBusinessSummary': 'Turning Point Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, engages in designing and '
                        'developing novel small molecule targeted oncology '
                        'therapies. It develops a pipeline of tyrosine kinase '
                        'inhibitors (TKIs) that targets genetic drivers of '
                        'cancer in TKI-na√Øve and TKI-pretreated patients. The '
                        "company's lead drug candidate repotrectinib is being "
                        'evaluated in an ongoing Phase I/II trial called '
                        'TRIDENT-1 for the treatment of patients with ROS1+ '
                        'advanced non-small-cell lung cancer (NSCLC) and '
                        'patients with ROS1+, NTRK+, or ALK+ advanced solid '
                        'tumors. Its pipeline also includes multi-targeted '
                        'drug candidates TPX-0046, a RET/SRC inhibitor; '
                        'TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a '
                        'preclinical ALK inhibitor. The company was founded in '
                        '2013 and is headquartered in San Diego, California.',
 'longName': 'Turning Point Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 2481334784,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_253779426',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -119302000,
 'nextFiscalYearEnd': 1640908800,
 'open': 61.21,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '858 926 5251',
 'previousClose': 62.21,
 'priceHint': 2,
 'priceToBook': 5.6484094,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 62.01,
 'regularMarketDayLow': 59.16,
 'regularMarketOpen': 61.21,
 'regularMarketPreviousClose': 62.21,
 'regularMarketPrice': 61.21,
 'regularMarketVolume': 185025,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 41341800,
 'sharesPercentSharesOut': 0.0692,
 'sharesShort': 2858794,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2740521,
 'shortName': 'Turning Point Therapeutics, Inc',
 'shortPercentOfFloat': 0.098500006,
 'shortRatio': 9.1,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'TPTX',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -3.699,
 'twoHundredDayAverage': 56.160538,
 'volume': 185025,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.tptherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92121'}